BPAX trial failure. ARIA & OREX to raise cash. CERS shelf + ANTH news

Dec 14, 2011 No Comments by

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) said today that it failed its two pivotal Phase 3 LibiGel efficacy trials and did not meet the co-primary or secondary endpoints. In the first trial, called BLOOM-1, patients who received LibiGel showed an increase of 1.47 days with a satisfying sexual event compared with 1.26 days for those who received the placebo gel, with p=0.463. The total number of satisfying sexual events of 3.87 was recorded in the LibiGel group while 3.52 satisfying sexual events was recorded in the placebo group, with p=0.698. In the second trial p value of 0.214 was recorded. Subjects in BLOOM-1 showed an increase in mean sexual desire of 0.03 over placebo, p=0.672, while those in BLOOM-2 demonstrated an increase in mean sexual desire of 0.03 compared to placebo, p=0.48. It noted that the LibiGel Phase 3 cardiovascular and breast cancer safety study will continue but will evaluate the value of continuing the trial.

Cerus Corporation (NASDAQ:CERS) filed a mixed shelf enabling it to issue stock and warrants to the value of $150m from time to time.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has commenced an underwritten public offering of shares of its common stock. The size of the offering was not released.

Orexigen Therapeutics, Inc. (Nasdaq: OREX) also said it intends to offer stock and warrants in an underwritten public offering. The size of the offering was not released.

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that the VISTA-16 Data Safety Monitoring Board (DSMB)  recommended the Phase 3 trial continue without change.  The interim efficacy analysis of the primary endpoint is scheduled to occur after 50% of the primary endpoint events in the VISTA-16 clinical study have been collected. It mentioned last month that it expected the interim efficacy analysis to take place this quarter.

 

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “BPAX trial failure. ARIA & OREX to raise cash. CERS shelf + ANTH news”

Leave a Reply